Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Fisetin has been extensively studied in preclinical cancer research, showing anti-proliferative, pro-apoptotic, and anti-angiogenic effects across numerous cancer cell lines and animal tumor models. This page provides context for that research while making absolutely clear that fisetin is not a cancer treatment and should never be used as a substitute for evidence-based oncology care. IMPORTANT DISCLAIMER: Fisetin has not been shown to treat, cure, or prevent cancer in humans. No human cancer trial with fisetin has been published. This page is for educational context only.
This Page Changed How You Think About Energy. Now Change How You Live.
Knowledge without action is just entertainment. Apply what you've learned and give your cells the support science says they need.
Detailed Evidence
SCOPE OF PRECLINICAL CANCER RESEARCH Published in vitro (cell culture) studies have examined fisetin effects on cell lines representing: lung cancer (non-small cell, small cell); colon/colorectal cancer; breast cancer (ER+, triple-negative); prostate cancer; pancreatic cancer; bladder cancer; melanoma; and cervical cancer. In these models, fisetin generally inhibited cell proliferation, induced apoptosis, and reduced invasion/migration markers. PROPOSED ANTI-CANCER MECHANISMS Cell cycle arrest: Fisetin has been shown to arrest cancer cells at G2/M or G1/S checkpoints, preventing uncontrolled division. Apoptosis induction: Fisetin activates the intrinsic apoptotic pathway (caspase-9/caspase-3) and modulates the extrinsic pathway (Fas/FasL) in cancer cells. Anti-angiogenesis: Fisetin inhibits VEGF signaling, potentially reducing tumor blood supply formation. Metastasis inhibition: In vitro, fisetin reduces MMP-2/MMP-9 expression and inhibits cancer cell migration and invasion. CONCENTRATIONS AND DOSES IN CANCER RESEARCH Critical context: the concentrations showing anti-cancer effects in cell culture typically range from 10-100 μM. Given fisetin's low oral bioavailability (<10%), achieving these concentrations in human tumor tissue through oral supplementation is highly unlikely. This represents a fundamental translational barrier that is often understated in popular discussions of fisetin's anti-cancer properties. ANIMAL TUMOR MODELS In xenograft models (human cancer cells implanted in immunodeficient mice), fisetin administration (typically by injection, not oral) reduced tumor growth by 30-60% across various cancer types. However, xenograft models have very poor predictive value for human cancer treatment — the vast majority of compounds showing efficacy in xenografts fail to demonstrate meaningful clinical benefit in human trials. WHY THIS RESEARCH DOES NOT SUPPORT CANCER TREATMENT CLAIMS Cell culture anti-cancer effects are common among polyphenols and do not predict human efficacy. Animal xenograft models have a dismal translation rate to human oncology. Oral bioavailability limitations make tumor tissue exposure at effective concentrations unlikely. No human cancer trial with fisetin has been registered or published. Self-treating cancer with dietary supplements instead of evidence-based therapies can be dangerous and potentially life-threatening.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
Your Future Self Will Thank You (Or Wonder Why You Waited)
Cellular damage is cumulative. The sooner you support your mitochondria, the more years of vitality you protect.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Can fisetin treat cancer?
No. Fisetin has not been shown to treat, cure, or prevent cancer in humans. No human cancer trial with fisetin has been published. Fisetin should never be used as a substitute for evidence-based oncology care.
What cancers has fisetin been studied against?
In vitro studies have examined fisetin effects on cell lines representing lung, colon/colorectal, breast (ER+, triple-negative), prostate, pancreatic, bladder cancer, melanoma, and cervical cancer.
How does fisetin affect cancer cells in the lab?
Fisetin inhibits cell proliferation, induces apoptosis via caspase-9/3 and Fas/FasL pathways, arrests cell cycle at G2/M or G1/S checkpoints, inhibits VEGF (anti-angiogenesis), and reduces MMP-2/MMP-9 (anti-metastasis).
Should cancer patients take fisetin?
Patients undergoing cancer treatment should not take fisetin without oncologist approval due to potential CYP3A4/CYP1A2 drug interactions with chemotherapy drugs. Unsupervised use can be dangerous.
Is fisetin a cancer cure?
Absolutely not. No human evidence supports fisetin as a cancer cure. Cell culture and animal model effects do not predict human efficacy. Self-treating cancer with supplements can be life-threatening.
What concentrations show anti-cancer effects?
Cell culture anti-cancer effects typically require 10-100 μM concentrations. Given fisetin's <10% oral bioavailability, achieving these concentrations in human tumor tissue through oral supplementation is highly unlikely.
Has fisetin been tested in human cancer trials?
No. No human cancer clinical trial with fisetin has been published or registered on ClinicalTrials.gov as of 2026. All cancer evidence is preclinical only.
Do xenograft models predict human cancer treatment?
No. Xenograft tumor models have a dismal translation rate to human oncology — the majority of compounds showing efficacy in xenografts fail in human clinical trials.
Can fisetin prevent cancer?
No human evidence supports fisetin for cancer prevention. Epidemiological associations between flavonoid intake and reduced cancer incidence cannot be attributed to fisetin specifically.
Is it dangerous to use fisetin instead of cancer treatment?
Yes. Self-treating cancer with dietary supplements instead of evidence-based therapies can be dangerous and potentially life-threatening. Treatment delays reduce survival. Always consult an oncologist.
Does fisetin affect tumor blood supply?
In cell culture, fisetin inhibits VEGF signaling, potentially reducing tumor blood supply formation (anti-angiogenesis). This has not been demonstrated in human studies.
Could fisetin interact with chemotherapy?
Yes. Potential CYP3A4/CYP1A2 interactions between fisetin and chemotherapy drugs make unsupervised use in cancer patients potentially dangerous. Always inform your oncologist about all supplements.
What is the translational gap in cancer research?
The gap between in vitro effective concentrations (10-100 μM) and achievable human plasma levels (low μM to nM) is the central translational barrier for fisetin's preclinical anti-cancer findings.
Are there better-studied anti-cancer supplements?
Many common polyphenols and flavonoids show similar in vitro anti-cancer effects — this is extremely common and rarely clinically relevant. No dietary supplement is an evidence-based cancer treatment.
What would it take to test fisetin for cancer?
Phase I-III clinical trials with oral fisetin in cancer patients, measuring tumor response, progression-free survival, and overall survival, with proper dose-finding and safety monitoring.
Key Research Facts
Fisetin has demonstrated anti-proliferative, pro-apoptotic, and anti-angiogenic effects in cell lines representing 8+ cancer types.
Moderate EvidenceSundarraj et al., Biomedicine & Pharmacotherapy — doi:10.1016/j.biopha.2017.10.164
In xenograft models, fisetin administration (typically injected, not oral) reduced tumor growth by 30-60% across various cancer types.
Moderate EvidenceSundarraj et al., Biomedicine & Pharmacotherapy — doi:10.1016/j.biopha.2017.10.164
Cell culture anti-cancer concentrations (10-100 μM) are far above achievable human plasma levels with standard oral fisetin supplementation.
Strong EvidenceGrynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159
No human cancer clinical trial with fisetin has been published or registered on ClinicalTrials.gov as of 2026.
Strong EvidenceClinicalTrials.gov — registry search
Many common polyphenols and flavonoids show in vitro anti-cancer effects — this is extremely common and rarely clinically relevant.
Strong EvidenceGeneral cancer research — Multiple reviews
Xenograft tumor models have a dismal translation rate to human oncology — the majority of compounds with xenograft efficacy fail in human trials.
Strong EvidenceCancer drug development statistics — Hutchinson & Kirk, 2011
Fisetin induced apoptosis via intrinsic (caspase-9/3) and modulated extrinsic (Fas/FasL) pathways in cancer cell lines.
Moderate EvidenceSundarraj et al., Biomedicine & Pharmacotherapy — doi:10.1016/j.biopha.2017.10.164
Fisetin should NEVER be used as a substitute for evidence-based oncology treatment — treatment delays reduce survival.
Strong EvidenceOncology clinical guidelines — NCCN guidelines
Potential CYP3A4/CYP1A2 interactions between fisetin and chemotherapy drugs make unsupervised use in cancer patients potentially dangerous.
Moderate EvidenceGrynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159
Epidemiological associations between flavonoid intake and reduced cancer incidence cannot be attributed to fisetin specifically.
Moderate EvidenceEpidemiological studies — Multiple population studies
Citations & External Resources
ClinicalTrials.gov — Search: Fisetin
PubMed — Fisetin research
EBioMedicine — Yousefzadeh et al. 2018
NCT06133634 — Fisetin Vascular Function Trial
Biomedicine & Pharmacotherapy — Sundarraj et al. 2018 (Cancer Preclinical)
Frontiers in Chemistry — Grynkiewicz & Demchuk 2019 (Bioavailability)
The Most Important Health Decision You'll Make This Year
It's not a gym membership. It's not a diet. It's supporting the 37 trillion cells that make everything else possible.
Related Reading
Fisetin: The Complete Evidence-Based Guide
Fisetin & Healthy Aging: What Research Shows
Fisetin Bioavailability: Why Formulation Matters
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026